Clinical Trial Update: 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma [Phase 2]

View source ↗

Summary

This Clinical Trial Update reports the completion of a Phase 2 study evaluating 131I-MIBG for treating patients with refractory or relapsed neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 131I-MIBG (metaiodobenzylguanidine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED